Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88165859 |
LAW OFFICE ASSIGNED |
LAW OFFICE 110 |
MARK SECTION |
MARK |
FIRSTCARE (see, http://uspto.report/TM/88165859/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
FIRSTCARE |
OWNER SECTION (current) |
NAME |
USPharma Ltd. |
MAILING ADDRESS |
13900 NW 57th Court |
CITY |
Miami Lakes |
STATE |
Florida |
ZIP/POSTAL CODE |
33014 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
OWNER SECTION (proposed) |
NAME |
USPharma Ltd. |
MAILING ADDRESS |
13900 NW 57th Court |
CITY |
Miami Lakes |
STATE |
Florida |
ZIP/POSTAL CODE |
33014 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
William West |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
W-L-O@outlook.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
william.west@uspharmaltd.com |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
William West |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
W-L-O@outlook.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
william.west@uspharmaltd.com |
DOCKET/REFERENCE NUMBER |
11009-FC |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations and substances for the treatment of allergy symptoms, bacterial infections, cough, inflammation, nasal congestion,
pain, sleep disorders, ulcers, and viral infections |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
3 |
ONGOING EFFORT |
promotional activities ; steps to acquire distributors ; tooling and packaging |
ALLOWANCE MAIL DATE |
03/19/2019 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/manesh dixit/ |
SIGNATORY'S NAME |
Manesh Dixit |
SIGNATORY'S POSITION |
chief executive officer (CEO) |
DATE SIGNED |
09/15/2020 |
SIGNATORY'S PHONE NUMBER |
(305) 698-4600 |
FILING INFORMATION |
SUBMIT DATE |
Wed Sep 16 10:26:34 ET 2020 |
TEAS STAMP |
USPTO/ESU-XXXX:XXXX:XXXX:
XXX:XXXX:XXXX:XXXX:XXXX-2
0200916102634250810-88165
859-750ad9893f859e79a2954
34cf08d992be870a24994f5ed
808f1ab5d181e16cef79-CC-2
6325124-20200915155550486
792 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: FIRSTCARE (see, http://uspto.report/TM/88165859/mark.png)
SERIAL NUMBER: 88165859
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: USPharma Ltd., having an address of
13900 NW 57th Court
Miami Lakes, Florida 33014
United States
Email: XXXX
Proposed: USPharma Ltd., having an address of
13900 NW 57th Court
Miami Lakes, Florida 33014
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 03/19/2019.
For International Class 005:
Current identification: Pharmaceutical preparations and substances for the treatment of allergy symptoms, bacterial infections, cough, inflammation, nasal congestion, pain, sleep disorders, ulcers,
and viral infections
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: promotional activities ; steps to acquire distributors ; tooling and packaging
Correspondence Information (current):
William West
PRIMARY EMAIL FOR CORRESPONDENCE: W-L-O@outlook.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): william.west@uspharmaltd.com
Correspondence Information (proposed):
William West
PRIMARY EMAIL FOR CORRESPONDENCE: W-L-O@outlook.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): william.west@uspharmaltd.com
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /manesh dixit/ Date Signed: 09/15/2020
Signatory's Name: Manesh Dixit
Signatory's Position: chief executive officer (CEO)
Signatory's Phone: (305) 698-4600
RAM Sale Number: 88165859
RAM Accounting Date: 09/16/2020
Serial Number: 88165859
Internet Transmission Date: Wed Sep 16 10:26:34 ET 2020
TEAS Stamp: USPTO/ESU-XXXX:XXXX:XXXX:XXX:XXXX:XXXX:X
XXX:XXXX-20200916102634250810-88165859-7
50ad9893f859e79a295434cf08d992be870a2499
4f5ed808f1ab5d181e16cef79-CC-26325124-20
200915155550486792